Access Consortium Procedure
Access Consortium Procedure
The Access Consortium Procedure is a collaborative initiative by regulatory authorities from several countries (e.g. Australia (Therapeutic Goods Administration, TGA); Canada (Health Canada); Singapore (Health Sciences Authority, HSA); Switzerland (Swissmedic); United Kingdom (Medicines and Healthcare products Regulatory Agency, MHRA). The objective is to streamline and align regulatory processes, ensuring quicker patient access to safe and effective medicines. It involves sharing information and resources among member countries to improve drug approval efficiency.
Solutions you may be interested in
Questions? Get the answers from our expert team
No two product development paths are the same. Talk to our experts about your development challenges and we will provide you actionable recommendations.